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Summary The platinum drug chemosensitivity of five human cervical squamous cell carcinoma cell lines
(HX/151, HX/155, HX/156, HX/160 and HX/171) derived from previously untreated patients has been
determined. Compared to our data obtained previously using human ovarian carcinoma cell lines, all five lines
were relatively resistant to cisplatin, carboplatin, iproplatin and tetraplatin. One of the lines (HX/156) was
exceptionally sensitive to the novel platinum (IV) ammine/amine dicarboxylates JM216 {bis-acetatoammine
dichloro (cyclohexylamine) platinum (IV)) and JM221 {ammine dibutyrato dichloro (cyclohexylamine)
platinum (IV)). The range in IC50 values across the five lines was approximately 2.5-fold for cisplatin,
carboplatin and iproplatin, 13-fold for tetraplatin and JM216, and 25-fold for JM221. No significant
correlation (P>0.05) was observed between platinum drug chemosensitivity and either glutathione levels or
cadmium chloride sensitivity, an indicator of metallothionein levels. In addition, there was no significant
correlation (P> 0.05) between cisplatin cytotoxicity and intracellular cisplatin accumulation or JM216 cytotox-
icity and intracellular JM216 accumulation over the dose range 5-100 JM (2 h exposure). The exceptional
sensitivity of HX/156 to JM216 appears, at least partially, to be a result of enhanced accumulation of
JM216.
An 8.6-fold acquired cisplatin resistant stable variant of HX/155 has been generated in vitro. Intracellular
cisplatin accumulation was reduced by 2.4 ± 0.3-fold (mean ± s.d.) in HX/155cisR across the dose range
1-1OOILM (2h exposure). Glutathione levels in HX/155cisR were elevated by 1.3-fold in terms of protein
content and by 1.6-fold in terms of cell number. HX/155cisR was 1.9-fold resistant to cadmium chloride. Total
platinum bound to DNA after cisplatin exposure (10, 25, 50 or 100 JM for 2 h) was 3.6 ± 0.6-fold
(mean±s.d.) lower in HX/155cisR. Hence the mechanism of acquired cisplatin resistance in HX/155cisR
appears to be multifocal, with reduced intracellular drug accumulation and elevated glutathione and metal-
lothionein levels combining to reduce DNA platination levels. While HX/155cisR was cross-resistant to
tetraplatin and carboplatin, novel platinum (II) and (IV) ammine/amine complexes, including JM216 and
JM221, partially circumvented resistance (resistance factors of 1.5-2). Non cross-resistance was observed to
iproplatin and nine non-platinum anticancer agents. Intracellular tetraplatin accumulation was reduced by
1.8 ± 0.1-fold (mean ± s.d.) in HX/I55cisR across the dose range 1-100 tM (2 h exposure). In contrast, after
JM216 exposure (1 1I001M for 2 h), no significant difference in intracellular platinum levels between HX/155
and HX/155cisR was observed. Hence the reduction in intracellular drug accumulation by HX/155cisR is
similar for cisplatin and tetraplatin, resulting in cross-resistance to tetraplatin. HX/155cisR appears to be
unable to retard the accumulation of JM216 which is therefore capable of partially circumventing resis-
tance.
In England and Wales the incidence of carcinoma of the
cervix is 4,500 new cases per year with an overall 5 year
survival rate of 58% (Cancer Research Campaign, 1992).
95% of cervical neoplasms are derived from squamous cell,
with the remainder adenocarcinomas. The disease accounts
for approximately 3% of female cancer deaths. In recent
years, despite an overall decrease in incidence primarily due
to Papanicolaou's smear screening, there has been an appar-
ent increase in incidence amongst younger women (<35
years) (Russell et al., 1987; Smales et al., 1987). Whilst the
prognosis for the majority of patients is good through the
treatment of early stage disease by surgery and radiotherapy,
there is a need for active chemotherapeutic agents for more
advanced stages of the disease.
The intrinsic chemosensitivity of cervical cancer appears to
be significantly less than that of ovarian cancer. Using
human tumour clonogenic assays from fresh biopsies, cer-
vical cancer in vitro drug sensitivity rates were as low as 20%
for some classes of standard chemotherapeutic agents
(Welander & Parker, 1987). Cisplatin has been shown to be
the most active single cytotoxic agent available for the treat-
ment of patients presenting with recurrent or metastatic cer-
vical cancer; no other agent has consistently shown objective
response rates of greater than 25% (Alberts & Mason-Liddil,
1989; Alberts et al., 1991). The effectiveness of cisplatin-
based chemotherapy, however, is commonly limited due to
both impaired drug distribution resulting from prior pelvic
irradiation, and drug resistance (both intrinsic and acquired
following treatment) (Alberts & Mason-Liddil, 1989; Alberts
et al., 1991). Because of these problems, the responses that
are observed with cisplatin are generally only of short dura-
tion. Furthermore, as has also been observed in advanced
ovarian cancer (Gore et al., 1989; Mangioni et al., 1989;
Eisenhauer et al., 1990), the recently developed cisplatin
analogues, carboplatin and iproplatin, have not shown
superior activity to cisplatin in randomised trials in advanced
cervical cancer (McGuire et al., 1989). Thus there remains an
urgent requirement to develop more effective chemothera-
peutic agents for the treatment of this disease.
Our drug discovery programme is aimed at developing
novel platinum-based anticancer drugs which are capable of
circumventing clinical resistance to cisplatin and carboplatin.
To assist in this objective, our efforts have concentrated
mainly on establishing preclinical models of intrinsic and
acquired cisplatin-resistant human ovarian carcinoma (Hills
et al., 1989; Harrap et al., 1990; Kelland et al., 1992a,c).
However, it may be equally important to target preclinical
evaluation and mechanistic studies upon somewhat less re-
sponsive tumour types such as cervical carcinoma. To date,
studies of cisplatin resistance mechanisms have focussed pre-
dominantly on tumour types such as ovarian carcinoma
(Andrews et al., 1985; Behrens et al., 1987; Kuppen et al.,
1988; Kikuchi et al., 1990; Kelland et al., 1992c), testicular
teratoma (Kelland et al., 1992b) and small cell lung cancer
(Hospers et al., 1988) where, typically, pairs of sensitive and
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acquired resistant variant cell lines have been established.
These investigations allude to a multifocal basis for resistance
involving one or more properties including reduced intracel-
lular accumulation, increased cytosolic detoxification by
glutathione and/or metallothionein, reduced DNA cross-link
formation and increased DNA repair (For review see De
Graeff et al., 1988; Kelley & Rozencweig, 1989; Andrews &
Howell, 1990; Canon et al., 1990).
In this present study, five cell line models of human cer-
vical squamous cell carcinoma (all derived from previously
untreated patients) have been used to determine the cytotoxic
properties of the clinically available platinum-based drugs
cisplatin, carboplatin, iproplatin and tetraplatin, and two
novel platinum (IV) ammine/amine dicarboxylates, a class of
compounds which exhibit selective cytotoxicity in intrinsically
cisplatin resistant human ovarian carcinoma cell lines (Kel-
land et al., 1992d). The correlation between platinum drug
cytotoxicity and glutathione levels, metallothionein levels and
intracellular platinum accumulation has been investigated. In
addition, in one cell line, acquired resistance to cisplatin has
been generated through in vitro exposure. The mechanistic
basis for acquired cisplatin resistance in this cell line has been
investigated. The ability of clinically available and novel
platinum complexes and non-platinum anticancer drugs to
circumvent this resistance has also been assessed.
Materials and methods
Cell lines
Five human cervical squamous cell carcinoma cell lines,
HX/151, HX/155, HX/156, HX/160 and HX/171 were used
in this study. Their establishment and biological characterisa-
tion have been described previously (Kelland et al., 1987;
Kelland & Tonkin, 1989). All five lines were derived from
previously untreated patients. The cell lines grew as mono-
layers in Dulbecco's Modified Eagles Medium (DMEM) con-
taining 10% foetal calf serum, 50 igml-l gentamicin, 2.5tg
ml-' amphotericin B, 2mM L-glutamine, lO gml-' insulin
and 0.5 lg ml-' hydrocortisone in a 10% C02, 90% air
atmosphere. Cells were periodically checked and found to be
free ofmycoplasma and used in these studies from passage 15
to 50.
Anticancer agents andchemicals
The platinum drugs, cisplatin (cis-diamminedichloroplatinum
(II)), carboplatin {cis-diammine-1,1-cyclobutane dicarboxyla-
toplatinum(II)), iproplatin (CHIP, cis-dichloro-trans-dihydro-
xo-cis-bis (isopropylamine) platinum (IV)), JM118 {ammine
dichloro(cyclohexylamine) platinum(II)), JM132 {ammine
tetrachloro(cyclohexylamine) platinum(IV)}, JM149 fammine-
cis-dichloro-trans dihydroxo (cyclohexylamine) platinum (IV)},
JM216 (bis-acetato-ammine dichloro (cyclohexylamine) plati-
num (IV)), JM221 {ammine dibutyratodichloro (cyclohexyl-
amine) platinum (IV)) and JM244 {ammine dibenzoatodi-
chloro (propylamine) platinum (IV)) were synthesised by and
obtained from the Johnson Matthey Technology Centre
(Reading, Berkshire, UK). Tetraplatin {(trans-d,l) 1,2-di-
aminocyclohexane tetrachloroplatinum (IV)) was kindly pro-
vided by Dr M. Wolpert-Defilippes (NCI, Bethesda, MD,
USA). The structures of these agents are shown in Figure
1.
Cadmium chloride, mitomycin C, vinblastine, chloram-
bucil, etoposide and sulphorhodamine B were obtained from
Sigma Chemicals (Poole, UK). 5-fluorouracil was obtained
from David Bull laboratories (Warwick, UK), bleomycin
from Lundbeck Ltd (Luton, UK), doxorubicin from Far-
mitalia Carlo Erba (Herts, UK) and melphalan from Bur-
roughs Wellcome (Bromley, UK). The novel antimicrotubule
agent, Taxotere (RP56976, NSC628503) was kindly provided
by Rhone-Poulenc Rorer, Antony, France.
Population doubling time determinations
Growth curves were constructed by seeding cells at low
density (1 x I05 cells/25 cm2 tissue culture flask); cells in dup-
licate flasks were then detached at 24 h intervals and counted
using a haemocytometer.
Cytogenetic analysis
Exponentially growing cultures were treated with 0.2 lagml'
colcemid for 4 h. Cells were then harvested by trypsinisation
and swollen in a hypotonic solution of 0.075 M KCI for
15 min at 37°C. Cells were then fixed with a mixture of 1 part
glacial acetic acid: 3 parts methanol and dropped onto slides.
Spreads were air-dried and stained with 5% Giemsa for
10 min. At least 60 metaphase spreads were counted for each
line.
Assessment ofcytotoxicity
All agents were dissolved immediately before use in either
water, 0.9% saline (for cisplatin, iproplatin, tetraplatin,
JM118, JM132, JM149 and JM216), absolute ethanol (for
chlorambucil, JM221 and JM244) or 95% ethanol containing
2% hydrochloric acid (for melphalan). Where ethanol was
used, the final concentration of solvent in the growth medium
did not exceed 0.5%; this concentration had no inhibitory
effect on cell growth.
Cytotoxicity was assessed using the sulphorhodamine B
(SRB) assay (Skehan et al., 1990). This was performed as
described previously (Mistry et al., 1991; Kelland et al.,
1992d). Briefly, single viable cells were seeded into 96-well
microtitre plates (5 x 103 1 x 104cells/well in 200jl of
growth medium) and incubated overnight. Serial dilutions of
drug were then added to quadruplicate wells. Exposure was
generally continuous for 96 h. Where 2 h exposures were
used, drug was removed from the cells after 2 h by washing
sequentially with phosphate buffered saline (PBS; pH 7.2)
and growth medium at 37°C, and the cells then incubated for
a further 96 h in 200glI drug-free growth medium. Basic
amino acid content/well was then analysed using 0.4% SRB
in 1% acetic acid. The IC50 (50% inhibitory concentration)
was determined.
Indirect quantitation ofmetallothionein levels
Metallothionein levels were measured indirectly by determin-
ing sensitivity of the cell lines to cadmium chloride using a
96 h continuous exposure SRB assay as described above.
Resistance to cadmium chloride has been shown to be
associated with elevated metallothionein levels resulting from
gene amplification, increased gene transcription and increased
mRNA stability (Hamer, 1986).
Glutathione (GSH) assay
Cellular GSH content was determined, in cells grown under
identical conditions to those used for the assessment of
cytotoxicity, as described previously (Mistry et al., 1991).
Approximately 1 x 106 cells were seeded into triplicate 25 cm2
tissue culture flasks and incubated overnight. Cells were then
washed twice with 25 ml ice-cold PBS and cellular GSH
extracted by a 10 min incubation at 40C with 2 ml of ice-cold
0.6% sulphosalicylic acid (SSA) with occasional shaking.
Total GSH in the extract was then determined by an enzy-
matic assay utilising glutathione reductase (Griffiths, 1980).
Protein (precipitated by the SSA) was determined after solu-
bilisation in 2 ml of 1 M sodium hydroxide according to
Lowry et al. (1951). The GSH content was expressed either
as nmol GSH/mg protein or nmol GSH/106 cells, cell counts
being carried out on parallel flasks.
Intracellular platinum accumulation
Approximately 3 x 106 cells growing exponentially in tripli-
cate 25 cm2 tissue culture flasks were exposed to cisplatin,242 K.J. MELLISH
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Figure 1 Structures of the platinum complexes studied.
tetraplatin or JM216 at concentrations from 1,100 jAM for
2 h. Immediately after exposure, cells were washed three
times with 25 ml ice-cold PBS, scraped and harvested in
0.5 ml PBS. Samples were then sonicated at 4°C (Soniprep
150, Fisons, Loughborough, UK) and total platinum content
determined by flameless atomic absorption spectroscopy
(FAAS) (Perkin Elmer model 1 lOOB and HGA700). Intracel-
lular platinum levels were expressed as nmol Ptmg-' protein,
protein content being determined from a 50 ,sl aliquot of cell
sonicate (which had been digested overnight in 200 JlI of 1 M
sodium hydroxide at 37C) according to Lowry et al. (1951).
Determination ofplatinum bound to the DNA
Approximately 8 x 107cells at near confluence in 175 cm2
tissue culture flasks were exposed to cisplatin at concentra-
tions from 10-100JM for 2 h. Cells were harvested by tryp-
sinisation and the DNA extracted by a modification of the
method of Kirby & Cook (1967). Cells were lysed (using
10mMTris, 10 mMEDTA, 0.15 MNaCl and 0.4% SDS) in
the presence of 1 mgml' proteinase K for Omin at 65°C,
then overnight at 37°C. The DNA was then isolated follow-
ing phenol extraction, ethanol precipitation, ribonuclease A
treatment, re-extraction and reprecipitation. The DNA was
hydrolysed in 0.5 ml 0.2% nitric acid and the platinum con-
tent of the hydrolysate determined by FAAS. DNA platina-
tion levels were expressed as nmol Pt g' DNA, the DNA
content of the hydrolysate being determined from an aliquot
according to Burton (1956).
Statistical analysis
Statistical significance was tested using an unpaired two-
tailed Student's t-test.CISPLATIN RESISTANCE IN CERVICAL CARCINOMA 243
Results
Characterisation ofthefive human cervical squamous cell
carcinoma cell lines
Platinum drug chemosensitivity Figure 2 shows the sensi-
tivity of HX/151, HX/155, HX/156, HX/160 and HX/171 to
the clinically used platinum-based drugs cisplatin, carbo-
platin, iproplatin and tetraplatin, and two novel platinum
(IV) ammine/amine dicarboxylates JM216 and JM221.
Results are expressed in terms of IC5o values (JLM) from a
96 h continuous exposure, SRB assay. The five lines all
showed similar cisplatin ICm values ranging from 0.9 to
2.4 gM. The data for carboplatin and iproplatin showed the
same pattern as for cisplatin except that the IC50 scale was
shifted up by one order of magnitude. Sensitivity to tetrap-
latin was more variable, with ICo values ranging from
0.9.LM in HX/156 to 1IILM in HX/160. HX/151, HX/155,
HX/160 and HX/171 all showed similar JM216 IC50 values
(range 0.6-1.7 JLM; i.e. similar to that seen for cisplatin),
whereas HX/156 was more sensitive with an IC5o of 0.13 tLM. JM221 was the most cytotoxic drug in all five lines. The data
for JM221 showed the same pattern as for JM216 except that
the IC50 scale was shifted down by one order of magni-
tude.
Glutathione (GSH) and metallothionein levels
Total GSH levels in HX/151, HX/155, HX/156, HX/160 and
HX/171 are shown in Table I. GSH levels varied across the
five lines by approximately 10-fold when expressed in terms
-i
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U
ofprotein content and 6-fold when expressed in terms of cell
number. Cellular protein content (mg protein/106cells) was
0.97, 0.22, 0.63, 0.77 and 0.92 for HX/151, HX/155, HX/156,
HX/160 and HX/l 71 respectively. No significant correlation
was observed between sensitivity to any of the six platinum-
based drugs and GSH levels when expressed in terms of
protein content (e.g. cisplatin: r - 0.23, P = 0.71) or cell
number (e.g. cisplatin: r = 0.78, P= 0.12). Table I also shows
the sensitivity of the five lines to cadmium chloride using a
96 h continuous exposure SRB assay, an indirect measure of
metallothionein levels. Cadmium chloride ICio values varied
by approximately 3-fold across the five lines; there was no
significant correlation with sensitivity to any of the six
platinum-based drugs (e.g. cisplatin: r = 0.32, P= 0.60).
Intracellularplatinum accumulation
Total intracellular platinum levels, expressed in terms of
protein content, for HX/151, HX/155, HX/156, HX/160 and
HX/171 immediately after 2 h exposure to cisplatin or JM216
at concentrations of 5, 10, 25, 50 and 100 gM are shown in
Figure 3. Within this concentration range, intracellular
platinum levels increased linearly with increasing dose. After
cisplatin exposure (Figure 3a), intracellular platinum levels
varied by approximately 4-fold across the five lines, being (on
average across the five concentrations used) highest in HX/155
and lowest in HX/156. After JM216 exposure (Figure 3b), intracellular platinum levels varied by approximately 2-fold
across the five lines, being (on average across the five concen-
trations used) highest in HX/155 and lowest in HX/160. No
significant correlation was observed between cisplatin (JM216)
HX/151 HX/155 HX/1 56 HX/160 HX/171
Cell line
Cisplatin [ Carboplatin a Iproplatin M Tetraplatin E JM216 E JM221
Figure 2 In vitro cytotoxicities (expressed as IC5o, iim; 96 h continuous exposure SRB assay) for cisplatin, carboplatin, iproplatin, tetraplatin, JM216 and JM221 against the five human cervical carcinoma cell lines HX/151, HX/155, HX/156, HX/160 and HX/171. Columns, means; bars,±s.d.; n> three experiments.
Table I Glutathione (GSH) and metallothionein levels in the five human cervical carcinoma cell
lines
HX/151 HX/155 HX/156 HX/160 HX/I171
GSH concentrationa
nmol mg-' protein 40.4 ± 14.2 81.8 ± 20.7 59.5 ± 5.7 8.6 ± 2.6 38.5 ± 6.8
nmol 10-6 cells 39.3 ± 13.4 17.7 ± 4.5 37.5 ± 5.2 6.6 ± 2.0 35.4 ± 6.2
Cadmium chloride sensitivityb
96 h IC50 (#M) 75.0 ± 9.9 65.0 ± 11.3 50.0± 5.7 33.0 ± 1.4 27.1 ± 0.1
Values represent mean ± s.d. an >two triplicate experiments. bn=three experiments.244 K.J. MELLISH
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Figure 3 Intracellular platinum accumulation immediately following 2h exposure of HX/151, HX/155, HX/156, HX/160 and
HX/171 cells to varying doses of cisplatin a, or JM216 b, Points, means; Bars, ± s.d.; n = two duplicate experiments.
cytotoxicity and intracellular platinum levels following cis-
platin (JM216) exposure at any concentration; e.g. at 25 LM
cisplatin: r = -0.65, P = 0.42; at 25gM JM216: r = -0.04,
P = 0.94. Intracellular platinum levels in HX/151, HX/155,
HX/156, HX/160 and HX/171 after JM216 exposure were
(on average across the five concentrations used) respectively
9, 5, 17, 6 and 15-fold higher than intracellular platinum
levels after cisplatin exposure; there was no significant cor-
relation between these ratios and the ratios of JM216: cisp-
latin cytotoxicity in the five lines (r=0.74, P=0.15).
Derivation ofacquired cisplatin resistance in HX/155
The parent HX/155 cell line was exposed to increasing concen-
trations of cisplatin from 25 nM up to a final concentration
of 10tLM over an 18 month period. Typically, the concentra-
tion was increased in 2-fold steps with three exposures at
each concentration. Exposure was continuous over 3 days;
the drug was then removed, and the cells were exposed again
when normal growth had resumed.
The derived cell line, HX/155cisR (which has not been
cloned), retained an identical morphological appearance to
that of the parent line under phase contrast microscopy. In
addition, there was no difference in population doubling time
(48 h) between the two cell lines. A cytogenetic analysis
revealed a mean chromosome number of 63.1 with four
double minutes per 100 mitotic spreads for HX/155, and 63.5
with 6 double minutes per 100 mitotic spreads for
HX/155cisR.
Cisplatin concentration-effect curves (96 h continuous
exposure SRB assay) for HX/155 and HX/155cisR are shown
in Figure 4. Mean ICm values were 0.72 LM for HX/155 and
6.13 gLM for HX/155cisR (resistance factor of 8.6). The level
of resistance observed for HX/155cisR remained stable in the
absence of further maintenance doses of cisplatin for at least
4 months.
Cross-resistance profile ofHX/JS5cisR
Cytotoxicity was assessed in HX/155 and HX/155cisR using
a 96h continuous exposure SRB assay. Resistance factors
(RF) were determined from IC50 HX/155cisR/IC50 HX/155.
Non-cross resistance was defined as RF<1.5.
Platinum-based drugs
Figure 5 shows the cross-resistance profile of HX/155cisR to
10 platinum-based drugs. HX/155cisR was 8.6-fold resistant
to cisplatin. It showed cross-resistance to tetraplatin and
partial cross-resistance to carboplatin, whilst iproplatin cir-
cumvented resistance. A low level of cross-resistance (RF
1.5-2) was observed to the novel platinum (II) ammine/CISPLATIN RESISTANCE IN CERVICAL CARCINOMA 245
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Figure 4 Growth inhibition of HX/155 (0) and HX/l55cisR
(0) vs cisplatin concentration (96 h continuous exposure SRB
assay). Points, means; bars,+ s.d.; n = three experiments.
amine complex JM118 and the novel platinum (IV) ammine/
amine complexes JM132, JM149, JM216, JM221 and
JM244.
Other chemotherapeutic agents
The cross-resistance profile of HX/155cisR to nine non-plati-
num anticancer agents (melphalan, chlorambucil, doxorubicin,
etoposide, mitomycin C, vinblastine, bleomycin, 5-fluorouracil
and taxotere) is shown in Table II. No cross-resistance was
observed to any of these agents; in fact some collateral
sensitivity was seen in HX/155cisR (RF<1).
HX/J55cisR: Mechanisms ofacquired cisplatin resistance and
its circumvention
We have attempted to determine the mechanistic basis for the
resistance of HX/155cisR to cisplatin, the observed cross-
resistance to tetraplatin (a platinum (IV) 1,2-diaminocyclo-
hexane (DACH) complex currently in Phase I clinical trial
(Anderson et al., 1986; Christian et al., 1991) and the partial
circumvention of resistance by the novel platinum (IV)
ammine/amine dicarboxylate JM216 (which is currently under-
going Phase I clinical evaluation as an orally administrable
drug at the Royal Marsden Hospital, Sutton).
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Resistance ofHX/155cisR to cisplatin, tetraplatin and JM216
after a 2 h exposure
Table III shows the cytotoxicity of cisplatin, tetraplatin and
JM216 in HX/155 and HX/155cisR using a 2 h exposure
SRB assay. Under these experimental conditions, HX/155cisR
was 9.9-fold resistant to cisplatin and cross-resistant to tetra-
platin, whilst JM216 partially circumvented resistance (RF
2.2). Two hour IC50 values ranged from 7.1 to 162pm; drug
concentrations from 1-100 ILM x 2 h were used in the follow-
ing experiments to reflect this range.
Intracellularplatinum accumulation
Figure 6 shows total intracellular platinum levels, expressed in terms of protein content, for HX/155 and HX/155cisR
immediately after 2h exposure to cisplatin, tetraplatin or
JM216 at concentrations of 1, 5, 10, 25, 50 and 100ZM.
Within this concentration range, intracellular platinum in-
creased with increasing dose in a linear fashion. After cis-
platin exposure (Figure 6a), platinum levels were on average
2.4±0.3(s.d.)-fold lower in HX/155cisR compared to the
parent line across the six concentrations used. A similar
result was obtained after tetraplatin exposure (Figure 6b), platinum levels being reduced by an average of 1.8 ± 0.1
(s.d.)-fold in HX/155cisR. In both cases, platinum levels were
significantly lower (P<0.01) in HX/155cisR at each concent-
ration tested. In contrast, after JM216 exposure (Figure 6c),
there was no signficant difference in platinum levels between
HX/155 and HX/155cisR at any concentration.
Glutathione (GSH) andmetallothionein levels
The results of experiments conducted to assess the possible
role of increased intracellular detoxification of platinum by
glutathione or metallothionein in HX/155cisR resistance are
shown in Table IV. Total GSH levels were increased by
1.3-fold in HX/155cisR compared to HX/155 when expressed
in terms of protein content, and by 1.6-fold when expressed
in terms of cell number (cellular protein content was
0.22mg protein/106 cells for HX/155 and 0.26mg protein/106
cells for HX/155cisR). In both cases this increase was statis-
tically significant at P<0.01. Metallothionein levels in HX/155
and HX/155cisR were measured indirectly by determining
sensitivity to cadmium chloride. HX/155cisR was 1.9-fold
resistant to cadmium chloride in terms of IC50 values from a
96h continuous exposure SRB assay.
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Figure 5 Cross-resistance profile (96h continuous exposure, SRB assay) of HX/155cisR vs HX/155 to cisplatin, carboplatin, iproplatin, tetraplatin, JMI 18, JM132, JM149, JM216, JM221 and JM244. Columns, means; bars, ± s.d.; n = three experiments. Resistance factor (RF) = IC50HX155cisR/IC30HX/l 55.246 K.J. MELLISH
Table II Cross-resistance profile of HX/155cisR to non-platinum
anticancer drugs
HX/155 HX/155cisR Resistance
Drug 96 h IC50 (gM) 96 h IC50 (gsM) factor (RF)
Melphalan 35.5 12.1 31.4 4.5 0.88
Chlorambucil 177.0 ± 43.6 163.3 ± 49.0 0.92
Doxorubicin 0.146 ± 0.054 0.109 ± 0.031 0.75
Mitomycin C 0.198 0.018 0.094 0.023 0.47
Etoposide 8.7 7.4 2.8 1.1 0.32
Vinblastine 0.0014 ± 0.0006 0.0011 ± 0.0006 0.79
Bleomycin 37.4 ± 21.5 17.1 ± 13.1 0.46
5-Fluorouracil 7.03 ± 2.57 1.99 ± 0.32 0.28
Taxotere 0.00084 ± 0.00005 0.00066 ± 0.00001 0.79
Values represent mean ± s.d. (n > three experiments). Resistance
factor (RF) = IC50 HX/155cisR/IC50 HX/155.
Table III Resistance of HX/155cisR to cisplatin, tetraplatin and
JM216 after a 2 h exposure
HX/155 HX/JSScisR Resistance
Agent 2h IC50 (gM) 2h IC50 (gM) factor (RF)
Cisplatin 7.1 3.7 70 18 9.9
Tetraplatin 12.1 7.8 162 61 13.4
JM216 45 28 98 3 2.2
Values represent mean ± s.d. (n = three experiments). Resistance
factor (RF) = IC50 HX/155cisR/1C50 HX/155.
Platinum DNA binding
The total amount of platinum bound to DNA after cisplatin
exposure (10, 25, 50 or 100PgM x 2h) for HX/155 and
HX/155cisR is shown in Figure 7. Platinum DNA binding
increased linearly with increasing dose up to 100 ELM. DNA
platination levels were significantly lower (P<0.05) in
HX/155cisR compared to the parent line at each dose point.
Across the entire concentration range, DNA platination
levels were reduced by an average of 3.6 ± 0.6 (s.d.)-fold in
HX/155cisR.
Discussion
In these experiments we have attempted to determine the
biochemical mechanisms underlying intrinsic and acquired
cisplatin resistance in human cervical squamous cell car-
cinoma. Acquired resistance may be the result of selection for
intrinsically resistant cells and/or the result of de novo induc-
tion of resistance mechanisms. Different mechanisms may
underlie intrinsic versus acquired resistance.
The cytotoxicity of various platinum-based complexes has
been determined in five human cervical squamous cell car-
cinoma cell lines. The cytotoxicity of cisplatin was similar in
all five lines, with IC50 values comparable to the least sen-
sitive cell lines from our previously described panel of human
ovarian carcinoma cell lines with a 100-fold range in cisplatin
sensitivity (Mistry et al., 1991; Kelland et al., 1992b).
Moreover, the lines were at least 5-fold more resistant to
cisplatin than our previously described cell line (GCT27)
derived from a patient presenting with testicular teratoma
(Kelland et al., 1992b). Thus the five cervical lines appear to
be intrinsically resistant to cisplatin. The cytotoxicity of
carboplatin and iproplatin was also similar in all five lines,
whereas the cytotoxicity of tetraplatin varied by approx-
imately 13-fold over the five lines. This correlates well with
results seen for a panel of ten human ovarian carcinoma cell
lines in which cisplatin, carboplatin and iproplatin elicited a
very similar pattern of response whereas that of tetraplatin
was completely different (Hills et al., 1989). IC50 values for
carboplatin, iproplatin and tetraplatin were all at the least
sensitive end of the human ovarian carcinoma cell line range
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Figure 6 Intracellular accumulation of platinum immediately
after a 2 h exposure of either HX/155 (0) or HX/ISScisR (0)
cells to varying doses of cisplatin a, tetraplatin b, or JM216 c,
Points, means; Bars, ± s.d.; n = two or three triplicate
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Table IV Glutathione (GSH) and metallothionein involvement in HX/155cisR
resistance
Fold
HX/155 HX/155cisR difference
GSH concentrationa
nmol mg-' protein 81.8 ± 20.7 108.0 ± 27.8 1.3
nmol 10-1 cells 17.7 ± 4.5 28.5 ± 7.4 1.6
Cadmium chloride sensitivityb
96h IC50 (tM) 65.0± 11.3 123.5 ±43.1 1.9
Values represent mean + s.d. an = four triplicate experiments. bn= three experiments.
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Figure 7 Binding of platinum to DNA immediately after a 2 h
exposure of either HX/155 (0) or HX/155cisR (0) cells to
varying doses of cisplatin. Points, means; bars, ± s.d.; n = three
experiments.
(Mistry et al., 1991; Kelland et al., 1992b). The cytotoxicity
of JM216 was similar to that of cisplatin in all of the lines
except HX/156, which was 13-fold more sensitive to JM216
than to cisplatin. This pattern was also observed for JM221,
except that the IC50 scale was shifted down by one order of
magnitude, with HX/156 having an IC50 value at the most
sensitive end of the human ovarian carcinoma cell line range
(Kelland et al., 1992d)
It has previously been reported that levels of GSH, the
major intracellular non-protein thiol, correlate with cisplatin,
carboplatin, iproplatin and tetraplatin sensitivity in a panel
of human ovarian carcinoma cell lines (Mistry et al., 1991),
and with cisplatin and iproplatin sensitivity in a series of
L1210 cell lines (Hrubisko et al., 1993). GSH levels were
measured in the five cervix lines and were found to vary by
10-fold across the five lines when expressed in terms of
protein content, and by 6-fold when expressed in terms of
cell number, despite the fact that the sensitivity to cisplatin,
carboplatin and iproplatin was similar for all five lines.
Moreover, there was no significant correlation (P>0.05)
between GSH levels and the variable sensitivity of the five
lines to tetraplatin, JM216 or JM221. The range of GSH
levels observed in the five intrinsically cisplatin resistant cer-
vix lines was similar to that observed in the ovarian cell line
panel, which contains both intrinsically resistant and sensitive
lines (Mistry et al., 1991), and the cisplatin sensitive GCT27
human testicular tumour cell line (Kelland et al., 1992b).
Levels of metallothioneins, which are composed of 30%
cysteine and constitute the major fraction of intracellular
protein thiols, have been shown to correlate with tetraplatin
sensitivity in a series of L1210 cell lines (Hrubisko et al.,
1993). Cadmium chloride sensitivity, an indirect measure of
metallothionein levels, varied by approximately 3-fold across
the five lines with HX/151 the most resistant and HX/171 the
most sensitive. All five lines were more resistant to cadmium
chloride than two cisplatin sensitive human ovarian car-
cinoma cell lines, CH1 (CdCl2IC505.1 p1M) and 41 M
(CdCl2IC5024.5 1kM) (Kelland et al., 1992c) and a cisplatin
sensitive human testicular tumour cell line, GCT27 (CdCl2
IC50 10.4,UM) (Kelland et al., 1992b). As with GSH levels, no
significant correlation (P>0.05) was observed between cad-
mium chloride sensitivity and the cytotoxicity of any of the
six platinum drugs investigated.
In an attempt to explain the intrinsic resistance of the five
cervix lines to cisplatin and the exceptional sensitivity of
HX/156 to the platinum (IV) ammine/amine dicarboxylates
JM216 and JM221, intracellular platinum accumulation was
measured in the five lines following cisplatin and JM216
exposure. Intracellular platinum levels following cisplatin
exposure showed no significant correlation with cisplatin
cytotoxicity (P> 0.05) and were not abnormally low com-
pared to two cisplatin sensitive human ovarian carcinoma
cell lines, CHl and 41M (Kelland et al., 1992c) and a cisp-
latin sensitive human testicular tumour cell line, GCT27
(Kelland et al., 1992b). Intracellular platinum levels after
JM216 exposure showed no significant correlation with
JM216 cytotoxicity (P> 0.05) and were higher at equimolar
doses than those observed after cisplatin exposure in all five
cell lines. The difference was greatest in HX/156, intracellular
platinum levels being 17-fold higher (on average across the
dose range 5-1I100M) after exposure to JM216 compared to
cisplatin. This may account for the 13-fold greater sensitivity
of HX/156 to JM216 compared to cisplatin. However, in
HX/171, which is only 2.7-fold more sensitive to JM216 than
to cisplatin, intracellular platinum levels were also much
higher (15-fold) after exposure to JM216 compared to cis-
platin. From these results it appears that the platinum drug
sensitivity/resistance of the five cervix lines cannot be
explained by one factor alone, and is probably determined by
a combination of several factors such as intracellular thiol
levels, intracellular platinum accumulation, DNA adduct for-
mation and DNA repair.
To further study the mechanistic basis of cisplatin resis-
tance in human cervical squamous cell carcinoma, an
acquired resistant variant of one of the lines, HX/155, has
been established by in vitro exposure to increasing concentra-
tions of cisplatin. The derived line, HX/lSScisR, is 8.6-fold
stably resistant to cisplatin and completely cross-resistant to
tetraplatin, a drug which was developed for clinical trial due
to the fact that it retained activity in acquired cisplatin
resistant variants of murine L1210 and P388 leukaemia cell
lines (Burchenal et al., 1977). Partial cross-resistance was
observed to carboplatin whereas iproplatin circumvented
resistance. The novel platinum (II) ammine/amine complex
JM118 and the novel platinum (IV) ammine/amine com-
plexes JM132, JM149, JM216, JM221 and JM244 all
exhibited resistance factors of between 1.5 and 2. Complete
circumvention of resistance to produce some collateral sen-
sitivity was achieved by all the non-platinum anticancer
agents examined. We have attempted to determine the
mechanisms underlying acquired resistance to cisplatin and
cross-resistance to tetraplatin in HX/155cisR. The mechanis-
tic basis for the partial circumvention of resistance by 'the
novel platinum (IV) ammine/amine dicarboxylate, JM216,
has also been investigated.
Reduced intracellular platinum accumulation has been248 K.J. MELLISH
shown to play a major role in acquired cisplatin resistance in
both human ovarian carcinoma (Andrews et al., 1988a; Hill
et al., 1992; Kelland et al., 1992c) and human non-small cell
lung cancer (Bungo et al., 1990) cell lines. Intracellular
platinum levels were significantly reduced by 2.4-fold in
HX/155cisR compared to HX/155 after cisplatin exposure,
suggesting that reduced accumulation is, at least, partially
responsible for the 8.6-fold acquired cisplatin resistance in
this cell line. This reduction in accumulation may result from
reduced uptake into the cell and/or increased efflux from the
cell. However, where it has been measured, no difference in
efflux between parent and acquired cisplatin resistant cell
lines has been observed (Teicher et al., 1987; Andrews et al.,
1988a; Kikuchi et al., 1990; Loh et al., 1992). After exposure
of HX/155 and HX/155cisR to tetraplatin, to which
HX/155cisR is completely cross-resistant, platinum levels
were 1.8-fold lower in HX/l55cisR (P<0.01). In contrast,
after exposure to JM216, no significant difference in platinum
levels between HX/155 and HX/155cisR was observed. Hence
reduced accumulation by HX/lSScisR appears to be specific
to some platinum complexes only.
Resistance to cisplatin may also be mediated by intracel-
lular thiols which bind to cisplatin in the cytosol to form an
inactive thioether. GSH has been implicated in acquired cis-
platin resistance in A2780 human ovarian carcinoma (Hamil-
ton et al., 1985; Behrens et al., 1987; Godwin et al., 1992)
and GLC4 human small cell lung carcinoma (Hospers et al.,
1988) cell lines. GSH levels were found to be significantly
increased in HX/155cisR compared to HX/155 by 1.3-fold
when expressed in terms of protein content, and by 1.6-fold
when expressed in terms of cell number. The relative impor-
tance of such elevated GSH levels in the resistance of
HX/155cisR may be assessed by investigating the extent by
which buthionine sulfoximine mediated GSH depletion is
able to reverse the resistant phenotype (Andrews et al., 1985;
Hamilton et al., 1985; Andrews et al., 1988b). Levels of
glutathione-S-transferase, which catalyses the conjugation of
GSH to electrophiles, may also be elevated as has been
reported previously (Teicher et al., 1987; Lewis et al., 1988;
Teicher et al., 1991). Elevated metallothionein levels have
been observed in acquired cisplatin resistant variants of a
number of human tumour cell lines (Kelley et al., 1988).
HX/1SScisR was 1.9-fold more resistant to cadmium chloride
than the parent line, suggesting that metallothionein levels
may be elevated in HX/155cisR.
There is considerable evidence that cisplatin exerts its
cytotoxic effects by binding to DNA to form bidentate intra-
strand and interstrand cross-links (Pinto & Lippard, 1985;
Roberts et al., 1986). After exposure of HX/155 and
HX/lSScisR to cisplatin, the total amount ofplatinum bound
to DNA was significantly reduced by 3.6-fold in HX/lSScisR.
This essentially reflects a reduction in DNA intrastrand
cross-links which account for the majority of platinum-DNA
adducts (Roberts et al., 1986). DNA interstrand cross-links
may also be reduced in HX/1SScisR. It is possible that the
elevated GSH levels in HX/lSScisR quench DNA-platinum
monoadducts, preventing rearrangement to interstrand cross-
links, and so resulting in a higher proportion of platinum
bound to the DNA in HX/lSScisR being in the form of
monofunctional adducts (Eastman 1987; Fram et al.,
1990).
From these results it appears that the mechanism of resis-
tance of HX/155cisR to cisplatin is multifocal, with reduced
intracellular accumulation and elevated glutathione and
metallothionein levels combining to reduce the amount of
cisplatin binding to the DNA. However, it is possible that
differeing mechanisms of resistance may have occurred
through the use of alternative selection procedures as
observed in another study (Andrews et al., 1989). An in-
creased ability to repair cisplatin-damaged DNA, which has
been demonstrated in acquired cisplatin resistant variants of
several cell lines including HeLa human cervical adenocar-
cinoma (Chao et al., 1991), GCT27 human testicular non
seminomatous germ cell tumour (Kelland et al., 1992b) and
A2780 human ovarian carcinoma (Masuda et al., 1988;
Masuda et al., 1990), cannot be ruled out. However, the
complete lack of cross-resistance of HX/155cisR to other
bifunctional alkylating agents such as melphalan, chloram-
bucil and mitomycin C provides indirect evidence to suggest
that increased DNA repair is unlikely to play a major role in
the resistance. Such a multifocal resistance mechanism has
previously been described in acquired cisplatin resistant sub-
lines of human small cell and non-small cell lung carcinoma,
melanoma, breast adenocarcinoma, and head and neck
squamous cell carcinoma (Teicher et al., 1987; Teicher et al.,
1991).
The cross-resistance of HX/155cisR to tetraplatin can be
attributed to the fact that the reduction in drug accumulation
by HX/155cisR is similar for both cisplatin and tetraplatin.
In contrast, the novel platinum (IV) ammine/amine dicar-
boxylate, JM216, overcomes reduced drug accumulation by
HX/155cisR and hence partially circumvents resistance. This
is consistent with previous reports which have shown that
platinum (IV) ammine/amine dicarboxylates can completely
circumvent resistance in an acquired cisplatin resistant
variant of the 41M human ovarian carcinoma cell line
(41McisR) in which the major mechanism of resistance is
reduced drug accumulation (Kelland et al., 1992c). These
agents are thought to overcome reduced drug accumulation
by 41McisR as a result of their enhanced lipophilicity over
cisplatin (Loh et al., 1992).
In summary, HX/151, HX/155, HX/156, HX/160, HX/171
and HX/155cisR cell lines provide in vitro preclinical models
of intrinsic and acquired cisplatin resistance in human cer-
vical squamous cell carcinoma; these may have utility along-
side human ovarian carcinoma models in the discovery and
evaluation of novel platinum-based anticancer drugs which
are able to circumvent cisplatin resistance in the clinic.
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